Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03707509

Recruitment Status : Active, not recruiting

First Posted : October 16, 2018

Last Update Posted : July 1, 2022

View this study on the modernized ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

Jiangsu HengRui Medicine Co., Ltd.

Study Description

Brief Summary:

This study is a randomized, placebo-controlled, double-blind, multicenter phase III clinical study. Target population is patients with recurrent/metastatic nasopharyngeal carcinoma who had not received systemic chemotherapy. Study objective is to compare the efficacy and safety of camrelizumab in combination with gemcitabine and cisplatin with placebo in combination with gemcitabine and cisplatin in study population in China. camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody.

Condition or disease	Intervention/treatment	Phase
Nasopharyngeal Carcinoma	Drug: Camrelizumab Drug: Placebos Drug: Gemcitabine Drug: Cisplatin	Phase 3

Detailed Description:

In this study, eligible subject will be randomized into study arm or control arm to accept study treatment. Treatment cycles of chemotherapy will be at most 6 weeks which will be decided by investigators. Progression-free survival (PFS) determined by the Independent Review Committee (IRC) will be the primary outcome measures.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	263 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:	Treatment
Official Title:	A Phase III, Randomized, Double-Blind, Multi-center Study to Investigate the Efficacy and Safety of Camrelizumab+Gemcitabine+Cisplatin Versus Placebo+Gemcitabine+Cisplatin in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma
Actual Study Start Date :	November 13, 2018
Actual Primary Completion Date :	August 1, 2021
Estimated Study Completion Date :	December 31, 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Cisplatin Gemcitabine Gemcitabine hydrochloride

Genetic and Rare Diseases Information Center resources: Nasopharyngeal Carcinoma

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Camrelizumab + Gemcitabine + Cisplatin subject will receive camrelizumab 200mg every 3 weeks, cisplatin 80mg/m2 on Day 1 of each 21 day, at most 6 cycles, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day, maximum 6 cycles	Drug: Camrelizumab Maximum 6 cycles for combined therapy. Camrelizumab maintenance. Other Name: SHR-1210 Drug: Gemcitabine Maximum 6 cycles for combined therapy. Other Name: Gemcitabine Hydrochloride for Injection Drug: Cisplatin Maximum 6 cycles for combined therapy. Other Name: Cisplantin Injection
Active Comparator: Placebos + Gemcitabine + Cisplatin subject will receive placebos every 3 weeks, cisplatin 80mg/m2 on Day 1 of each 21 day, at most 6 cycles, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day, maximum 6 cycles	Drug: Placebos Maximum 6 cycles for combined therapy. Other Name: Placebo - Concentrate Drug: Gemcitabine Maximum 6 cycles for combined therapy. Other Name: Gemcitabine Hydrochloride for Injection Drug: Cisplatin Maximum 6 cycles for combined therapy. Other Name: Cisplantin Injection

Outcome Measures

Primary Outcome Measures :

Progression-free survival (PFS) [ Time Frame: up to 24 month ]
PFS, defined as the time from randomization to the first occurrence of disease progression as determined by the Independent Review Committee according to RECIST v1.1 or death from any cause, whichever occurs first.

Secondary Outcome Measures :

Progression-free survival [ Time Frame: up to 24 month ]
Progression-free survival (PFS) assessed by investigators according to RECIST V 1.1
Objective Response Rate (ORR) [ Time Frame: up to 24 month ]
The percentage of patients with CR and PR assessed by investigators according to Recist v 1.1
Disease Control Rate (DCR) Disease Control Rate (DCR) [ Time Frame: up to 24 month ]
The proportion of patients who have achieved complete response， partial response and Stable disease assessed by investigators according to Recist v 1.1
Duration of Response (DoR) [ Time Frame: up to 24 month ]
According to Recist v 1.1 accessed by investigators
2 years Overall Survival (OS) rate [ Time Frame: up to 24 month ]
The percentage of patients overall survival in 2 years
Adverse Events (AEs) [ Time Frame: up to 24 month ]
All adverse event/Serious adverse event that occurred during the study period according to CTCAE v 4.03

Other Outcome Measures:

Antidrug Antibodies (ADAs) [ Time Frame: up to 24 month ]
To evaluate the incidence and titers of ADAs against camrelizumab

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Age ≥ 18 years and ≤75 years;
Subjects with histopathological diagnosis of nasopharyngeal carcinoma;
Primarily metastatic (stage IVB as defined by the International Union against Cancer and American Joint Committee on Cancer staging system for NPC, eighth edition) or recurrent NPC that is not amenable for local regional treatment or curative treatment;
Has not received prior systemic treatment;
Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status
Subject must have a measurable target lesion based on RECIST v1.1;

Exclusion Criteria:

Allergic to monoclonal antibodies, any camrelizumab components, gemcitabine, cisplatin and other platinum drugs;
Prior therapy as follow:
- Anti-PD-1 or anti-PD-L1;
- Received last dose of anticancer therapy (including chemotherapy, radiotherapy, targeted therapy, etc.) within 4 weeks of the first dose of study medication;
- Concurrent medical condition requiring the use of cortisol (>10mg/day Prednisone or equivalent dose) or other systematic immunosuppressive medications within 14 days before the study treatment. Except: inhalation or topical corticosteroids. Doses > 10 mg/day prednisone or equivalent for replacement therapy;
- Received major operations or serious injuries within 4 weeks of the first dose of study medication;
Not recovered to ≤CTCAE 1 from adverse events (except for hair loss) due to a previously anti-tumor treatment;
Pregnancy or breast feeding;

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03707509

Locations

Layout table for location information

China, Guangdong
Cancer Center of Sun-Yat Sen University (CCSYSU)
Guangzhou, Guangdong, China, 510060

Sponsors and Collaborators

Jiangsu HengRui Medicine Co., Ltd.

Investigators

Layout table for investigator information

Principal Investigator:	Li Zhang, MD	Cancer Center of Sun-Yat Sen University (CCSYSU)
Study Director:	Qing Yang, MD	Jiangsu HengRui Medicine Co., Ltd.

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Yang Y, Qu S, Li J, Hu C, Xu M, Li W, Zhou T, Shen L, Wu H, Lang J, Hu G, Luo Z, Fu Z, Qu S, Feng W, Chen X, Lin S, Zhang W, Li X, Sun Y, Lin Z, Lin Q, Lei F, Long J, Hong J, Huang X, Zeng L, Wang P, He X, Zhang B, Yang Q, Zhang X, Zou J, Fang W, Zhang L. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2021 Aug;22(8):1162-1174. doi: 10.1016/S1470-2045(21)00302-8. Epub 2021 Jun 23.

Layout table for additonal information

Responsible Party:	Jiangsu HengRui Medicine Co., Ltd.
ClinicalTrials.gov Identifier:	NCT03707509
Other Study ID Numbers:	SHR-1210-III-308
First Posted:	October 16, 2018 Key Record Dates
Last Update Posted:	July 1, 2022
Last Verified:	June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	No

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:	No
Studies a U.S. FDA-regulated Device Product:	No

Keywords provided by Jiangsu HengRui Medicine Co., Ltd.:


Nasopharyngeal Carcinoma PD-1 Antibody Cisplatin Gemcitabine

Additional relevant MeSH terms:

Layout table for MeSH terms

Carcinoma Nasopharyngeal Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Nasopharyngeal Neoplasms Pharyngeal Neoplasms Otorhinolaryngologic Neoplasms Head and Neck Neoplasms Neoplasms by Site	Nasopharyngeal Diseases Pharyngeal Diseases Stomatognathic Diseases Otorhinolaryngologic Diseases Gemcitabine Antineoplastic Agents Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action

To Top